MeiraGTx Holdings Announces Joint Venture with Hologen

Meiragtx Holdings ( (MGTX) ) has shared an announcement.

On March 9, 2025, MeiraGTx Holdings announced a strategic collaboration with Hologen Limited, a leader in generative AI models for clinical medicine, to form a joint venture called Hologen Neuro AI Ltd. This partnership aims to expedite the development of MeiraGTx’s AAV-GAD gene therapy for Parkinson’s disease and other CNS therapies, with Hologen providing up to $230 million in funding. MeiraGTx will receive $200 million upfront and retain a 30% stake in the joint venture, while Hologen will own a minority stake in MeiraGTx’s manufacturing subsidiary. The collaboration is expected to enhance MeiraGTx’s manufacturing capabilities and extend its cash runway, potentially accelerating other programs such as the AAV-hAQP1 Xerostomia program.

More about Meiragtx Holdings

MeiraGTx Holdings plc is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline that includes four late-stage clinical programs. These programs focus on the local delivery of small doses to achieve disease-modifying effects in inherited and common diseases, such as those affecting the eye, Parkinson’s disease, and radiation-induced xerostomia. The company is known for its innovative technology in optimizing capsids, promoters, and novel translational control elements to develop potent and safe viral vectors. MeiraGTx supports its pipeline with comprehensive in-house manufacturing capabilities, including five global facilities, two of which are licensed for GMP viral vector production.

YTD Price Performance: 2.23%

Average Trading Volume: 318,347

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $476.7M

See more insights into MGTX stock on TipRanks’ Stock Analysis page.